[Cold thinking on ten hot issues in the treatment of early breast cancer].
Zhonghua Wai Ke Za Zhi
; 60(3): 213-218, 2022 Mar 01.
Article
in Zh
| MEDLINE
| ID: mdl-35078295
ABSTRACT
With the development of new strategies like target therapy and immunotherapy, early breast cancer treatment has become more standardized, and the interval of disease free survival has been extended. Although guidelines and expert consensus have provided supports for clinical decision making, there are still some controversial issues in clinical practice, attributing to different treatment concepts, product indications and accessibility. These controversial issues would eventually affect the treatment of early breast cancer. This year in 2021, the approval of new indications of drugs like abemaciclib and the popularity of dual anti-human epidermal growth factor receptor 2 targeted drugs have promoted the change of treatment modalities for different types of early breast cancer. To this end, ten hot topics of early breast cancer are summarized according to their different molecular typing and treatment stages for discussion.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
Type of study:
Guideline
/
Prognostic_studies
/
Qualitative_research
Limits:
Female
/
Humans
Language:
Zh
Journal:
Zhonghua Wai Ke Za Zhi
Year:
2022
Document type:
Article
Affiliation country:
China